We recently received news from Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) about their clinical trials for what many hoped would become a knockout Alzheimer's drug.
The compound would have become the first to fully address the steady decline in memory the disease causes. But new tests showed the drug simply didn't work.
No doubt this was a setback for the firms, who sunk millions of dollars into developing the drug. And it's truly disappointing for millions of current Alzheimer's patients and their families.
But I don't think we should be worried.
As I see it, this is a setback, not a fatal flaw. Remember, no road to victory follows a straight path.
And this field is moving so quickly that a new drug - or novel therapy - could come along any day now to provide relief to the five million Americans who have this disease closely associated with aging.
After all, we are living in the Era of Radical Change, a period like none we've seen before. We see hundreds of important breakthroughs in high tech and biosciences every year. The pace of change comes so fast no one person on earth can begin to understand what it all means.
But I do know this.
Some of the brightest minds in the world are working to combat the memory loss and dementia brought on by Alzheimer's, as well as to find an outright cure.
I've been interested in this field for more than 30 years since I took a class on aging while getting my honors economics degree. And in just the last few weeks alone, I've read about several exciting new finds.
Let's take a look...
Alzheimer's Advance No. 1: Amyloid-Defeating IV Treatment
Consider the new drug from Baxter International Inc. (NYSE:BAX). Doctors say four patients who received the highest doses in trials showed no decline in memory or thinking skills. Of course, that's too small a sample to predict success at this point. But the results wowed experts attending a global industry meeting last month.
Patients receive this drug Gammagard through an IV. Technically, this type of drug is known as an immune globulin and is often to referred to as IVIG. It's distilled from donated blood. The Associated Press says half a dozen companies already sell IVIG to treat problems with blood and the immune system.
These antibodies may also help remove amyloid, the sticky plaque that clogs patients' brains and erodes memory and clear thinking.
Baxter intends to test Gammagard on 400 patients and have the results within a year. If the substance works as many believe it will, it could be huge. So far, those patients who have tried it love it.
"I feel that I haven't gone down, and that's good," says Jason Marder, a 70-year-old New Yorker. "I feel good. I'm very independent."
His wife Karin sounds even more thrilled: "He has slowed down, no question about it. His walk is a little slower, but that could also have a lot to do with age. He's still the Jason that I married. He's still there. We still have a wonderful relationship together. I'm grateful for every day that he's independent."
And who knows... we may not even need to take "drugs" at all.
Alzheimer's Advance No. 2: Fighting the Disease with Nutrition
You see, also last month, a clinical trial at MIT found that a "cocktail" of nutrients known as Souvenaid - and taken as a drink - can improve memory for those with an early form of Alzheimer's.
Souvenaid is a mixture of three naturally occurring compounds found in a healthy diet - choline, uridine, and the omega-3 fatty acid DHA (you get them by eating meat, nuts, eggs, fish, and flaxseed).
Researchers said Souvenaid combats Alzheimer's by stimulating the growth of new synapses, which, among other things, pass signals from one brain cell to another.
No one knows when health officials might approve Souvenaid and when it would come to market. But it will likely hit Europe first. Souvenaid comes from the healthcare division of Danone, a food firm known in the U.S. as The Dannon Co. Inc. (you probably know them for their yogurt).
Meantime, July brought another Alzheimer's breakthrough.
Alzheimer's Advance No. 3: Earlier Detection
Scientists said they can build a "timeline" of the disease long before symptoms appear.
To do so, a team at Washington University School of Medicine looked at families with a genetic risk. Some 128 subjects received blood and spinal fluid tests as well as brain scans and a check of their cognitive skills.
Researchers said they saw clear signs of how Alzheimer's progresses as much as 25 years in advance.
Another team was able to use walking patterns to identify cognitive decline and help with early diagnosis. In two studies - at the Mayo Clinic and the Basel Mobility Center in Switzerland -researchers used a computer to measure the stride length, cadence, and speed of participating walkers at two visits 15 months apart. Changes in a person's gait were an early predictor of cognitive decline.
This is the first time doctors were able to link a physical symptom to Alzheimer's disease.
Here's the thing. Getting early signs of Alzheimer's will help doctors provide better care for their patients. It also means that new drugs could begin combatting the disease much earlier, say at age 40.
That gives investors like us a double play. We buy stock in a company that sells a product to patients for many years.
And by getting rid of this scourge, we really will be able to enjoy our Golden Years after all.
Related Articles and News:
- Money Morning:
If Anyone Knows How to Make Money It's This Hot Tech IPO - Money Morning:
Cutting-Edge "Maple Seed" Drones are About to Reshape High-Tech Surveillance - Money Morning:
Experimental Brain Injury Treatments Could Be Worth Billions - Money Morning:
Breakthrough Tech Lets Users Surf the Web With Just Their Eyes
[epom]
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.